News & Perspective

Apr 21, 2017

Apr 21, 2017

ASP Scan (Weekly) for Apr 21, 2017

Marker for pneumonia antibiotics
MCR-1 cases in Italy
Novel antibiotic target
Penicillin-resistant pneumonia
ID stewardship consults
Steroid for sore throat
MRSA contamination
Chlorhexidine bathing
Candida in Peru
Azithromycin and abnormal heartbeat
Mutations in resistant bacteria

May 13, 2011

May 13, 2011

Study: Pigs susceptible to deadly Ebola strain

(CIDRAP News) – Canadian researchers have shown that an Ebola virus species that can kill humans can also infect pigs and spread among them, raising the specter of Ebola virus as a potential foodborne pathogen.

May 10, 2011

May 10, 2011

FDA approves Sanofi's intradermal flu vaccine

(CIDRAP News) – Sanofi Pasteur's intradermal influenza vaccine, which involves a shallow needle prick into the skin instead of deep into muscle tissue, has been approved by the US Food and Drug Administration (FDA), the company announced today.

Oct 31, 2008

Oct 31, 2008

Encouraging results reported for injectable flu drug

(CIDRAP News) – BioCryst Pharmaceuticals Inc. reported encouraging results this week in two phase 2 trials of its injectable antiviral drug, peramivir, a potential new treatment for influenza.

Peramivir is a neuraminidase inhibitor, like the licensed antivirals oseltamivir (Tamiflu), which is taken orally, and zanamivir (Relenza), inhaled as a powder.

Nov 15, 2007

Nov 15, 2007

THE PANDEMIC VACCINE PUZZLE Can we vaccinate enough people in time to matter?

Maryn McKennaContributing Writer

(CIDRAP News) – This in-depth article investigates the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. Its seven parts put advances in vaccine technology in perspective by illuminating the formidable barriers to producing an effective and widely usable vaccine in a short time frame.

Nov 14, 2007

Nov 14, 2007

Study finds greater, later role for antivirals in flu patients

(CIDRAP News) – Adults who are hospitalized with serious seasonal influenza infections are more likely to survive if they receive antiviral medications, and older patients may benefit even if treatment is delayed until more than 48 hours after their first symptoms, according to a new study by Canadian researchers.

Pages

Sort Results

 

Narrow results

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation 3M Gilead 
Grant support for ASP provided by

  Become an underwriter»